Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 Mpro Inhibitor
BFC204 is an inhibitor of the SARS-CoV-2 main protease (Mpro) that demonstrates a kinact/Ki value of 619 mol/s. This compound effectively disrupts the enzymatic activity of Mpro, which is essential for the viral replication process. BFC204 is utilized in research focused on antiviral drug development and the molecular mechanisms of SARS-CoV-2 pathogenesis. -
SARS-CoV-2 Mpro/RBD结合剂
(+)-Adlumidine is an isoquinoline alkaloid that acts as a potent inhibitor of SARS-CoV-2 by targeting the main protease (Mpro) and the receptor-binding domain (RBD) with IC50 values of 953.86 μM and 9.48 μM, respectively. This compound exhibits notable positive inotropic and positive chronotropic effects on cultured mouse embryonic cardiomyocytes. Additionally, (+)-Adlumidine is useful for research focused on cardiovascular diseases and mechanisms of SARS-CoV-2 infection. -
SARS-CoV-2 Viral Propagation Inhibitor
Covidcil-19 is a potent inhibitor targeting the frameshifting element (FSE) of SARS-CoV-2. By binding to the revised attenuator hairpin structure with a dissociation constant (Kd) of 11 nM, Covidcil-19 stabilizes its folded conformation, thereby impairing frameshifting efficiency. Importantly, it does not alter the RNA levels of the SARS-CoV-2 FSE. This compound serves as a valuable tool for investigating viral propagation mechanisms and presents potential applications in antiviral research against SARS-CoV-2. -
SARS-CoV-2 Mac1 Inhibitor
MDOLL-0229 is an antiviral reagent that targets the SARS-CoV-2 Mac1 protein, effectively repressing coronavirus replication. This compound demonstrates inhibitory activity against SARS-CoV-2 Mac1 with an IC50 value of 2.1 µM. MDOLL-0229 serves as a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and the development of antiviral strategies. -
SARS-CoV-2 Inhibitor
TKB272 is a selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively inhibits the infection and replication of various SARS-CoV-2 strains, including Omicron variants, with an IC50 of 0.7 µM and an EC50 as low as 2.6 nM in cellular assays. Additionally, TKB272 demonstrates a high safety profile with a CC50 of 98 µM, indicating minimal cytotoxicity. Its ability to significantly reduce replication in transgenic mouse models highlights its potential as a valuable tool for SARS-CoV-2 research. -
SARS-CoV-2 E Protein Inhibitor
SARS-CoV-2-IN-117 is a potent inhibitor of the SARS-CoV-2 E protein, targeting its interaction with the host ZO-1 PDZ2 domain. This compound exhibits significant antiviral activity, effectively reducing viral replication. SARS-CoV-2-IN-117 is suitable for research applications focused on understanding and mitigating COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-14 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 0.044 μM. This compound demonstrates excellent water solubility and exhibits no cytotoxic effects, making it suitable for in vitro studies. SARS-CoV-2 Mpro-IN-14 is valuable for research applications focusing on COVID-19 and the development of antiviral therapeutics. -
SARS-CoV-2 main protease (Mpro) Inhibitor
UAWJ246 is a covalent reversible inhibitor targeting the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.045 μM and a Ki of 0.036 μM. This compound demonstrates significant antiviral activity by effectively inhibiting SARS-CoV-2 viral replication while maintaining low cytotoxicity. UAWJ246 is suitable for research focused on SARS-CoV-2 infection and the development of therapeutic strategies for COVID-19. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-82 is a selective inhibitor targeting the programmed -1 ribosomal frameshift (PRF) mechanism in SARS-CoV-2. This compound effectively disrupts viral protein translation, thereby hindering the replication of the virus. It is primarily utilized in research applications focused on understanding the mechanisms of SARS-CoV-2 infection and developing antiviral strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-89 is a potent inhibitor targeting SARS-CoV-2. This compound enhances interferon type I (IFN-I) responses in A549.hACE2 cells upon viral infection, making it a valuable tool for studying antiviral mechanisms and developing therapeutic strategies against COVID-19. Its application in research facilitates a deeper understanding of the immune response to SARS-CoV-2. -
SARS-CoV-2 Inhibitor
PB49673382 is a potent inhibitor of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits viral replication and mitigates the cytopathic effects associated with the virus, with an IC50 value of 6.42 μM. This compound is useful for research applications focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
DB12055 is a covalent inhibitor targeting the 3CL protease of SARS-CoV-2. It demonstrates significant inhibitory activity against this viral protease, making it a valuable tool for research focused on COVID-19. Additionally, DB12055 may be useful for investigating metabolic disorders such as dyslipidemia and diabetes mellitus. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-30 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 value of 9.1 nM. This compound is critical for the study of SARS-CoV-2 biology and can be utilized in research focused on antiviral drug discovery and development. Its efficacy in inhibiting viral replication makes it a valuable tool for investigating therapeutic strategies against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
BFC220 is a covalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 2.77 μM. This compound is valuable for antiviral research, specifically in studies involving the inhibition of viral protease activity and the development of targeted therapies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-52 is a potent inhibitor targeting the SARS-CoV-2 virus, exhibiting an inhibitory potency characterized by a pIC50 of 0.3187. This compound demonstrates significant antiviral activity and is suitable for research applications aimed at understanding and mitigating SARS-CoV-2 infections. Its mechanisms may provide valuable insights into therapeutic strategies against COVID-19. -
SARS-CoV-2 Nsp12 Inhibitor
Nsp12-IN-2 is a SARS-CoV-2 Nsp12 inhibitor, specifically targeting the RNA-dependent RNA polymerase (RdRp) activity of the Nsp12-Nsp7-Nsp8 complex. This compound terminates RNA synthesis and inhibits the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 shows potential for research into SARS-CoV-2 infections, as well as studies involving other coronaviruses and RNA viruses. -
SARS-CoV Inhibitor
SARS-CoV-2 Mpro-IN-51 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 26 nM. This compound effectively targets the triple mutant variant L50F/E166A/L167F, making it a valuable tool for research into viral pathogenesis and therapeutic interventions. Its application extends to studies aimed at elucidating mechanisms of viral infection and drug resistance in SARS-CoV-2. -
SARS-CoV-2 3CL Protease Inhibitor
SARS-CoV-2 3CLpro-IN-33 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 1.5 nM. This compound demonstrates strong antiviral activity against SARS-CoV-2 in HEK293T-AT cells, with an EC50 of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 is suitable for research applications focused on understanding COVID-19 infection and developing therapeutic strategies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 PLpro-IN-1 is a non-covalent, competitive inhibitor specifically targeting the SARS-CoV-2 PLpro enzyme. It demonstrates significant biological activity with an IC50 of 15.06 μM and a Ki value of 22.93 μM. Furthermore, SARS-CoV-2 PLpro-IN-1 effectively inhibits the proliferation of Vero cells, exhibiting an IC50 of 7.47 μM. This compound is suitable for research applications focused on viral inhibition and understanding the mechanisms of SARS-CoV-2 replication. -
SARS-CoV Control
Remdesivir intermediate-1 is a synthetic precursor in the production of Remdesivir, an antiviral agent targeting SARS-CoV. This compound plays a crucial role in facilitating the synthesis of Remdesivir, which is used primarily for therapeutic intervention against COVID-19 and related viral infections. Its importance in research applications extends to antiviral drug development and mechanistic studies of RNA viruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-67 is a vitamin K derivative that serves as an inhibitor of SARS-CoV-2. It exhibits significant antiviral activity against SARS-CoV-2, with an EC50 of 64.8 μM in VeroE6/TMPRSS2 cells. This compound specifically targets and inhibits the activity of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), making it a valuable reagent for research applications in virology and the study of coronavirus infections. -
SARS-CoV-2 Inhibitor
Jobosic acid is a saturated fatty acid that functions as a selective inhibitor of SARS-CoV-2. It effectively inhibits the main protease (Mpro) and the spike receptor binding domain (RBD) interaction with ACE-2, demonstrating IC50 values of 7.5 μg/mL and 3 μg/mL, respectively. Jobosic acid also exhibits inhibitory effects on viral entry for the omicron variant of SARS-CoV-2, making it a valuable compound for research in antiviral therapies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-69 is a non-covalent inhibitor specifically targeting the SARS-CoV-2 main protease (Mpro) with an EC50 value of 7.4 μM. This compound demonstrates potent inhibitory activity against Mpro and also acts as a non-covalent inhibitor of papain-like protease (PLpro). It is suitable for studies aimed at understanding the mechanisms of SARS-CoV-2 replication and for the development of antiviral therapeutics. -
SARS-CoV-2 Mac1-ADP-ribose Inhibitor
F594-1001 is a selective inhibitor of the SARS-CoV-2 Mac1-ADP-ribose activity, demonstrating IC50 values of 8.5 μM, 68 μM, and 45 μM in AS, FP, and FRET assays, respectively. This compound directly interacts with the Mac1 enzyme, resulting in dose-dependent inhibition of ADP-ribosylhydrolase activity. F594-1001 is valuable for research focused on understanding SARS-CoV-2 biology and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Antiviral Agent
SARS-CoV-2-IN-102 is a potent inhibitor of the SARS-CoV papain-like protease (PLpro), demonstrating an IC50 of less than 100 nM. This compound exhibits significant antiviral activity against SARS-CoV-2, making it a valuable tool for research in the development of therapeutic agents targeting COVID-19. Its mechanism of action involves the disruption of viral replication, thereby providing insights into antiviral strategies and the efficacy of protease inhibitors in combating SARS-CoV-2 infections. -
SARS-CoV-2-specific Entry Inhibitor
SARS-CoV-2-IN-120 is a specific entry inhibitor targeting the SARS-CoV-2 spike protein. By binding to and trimerizing within the apex cavity of the spike trimer, it effectively blocks the interaction between the receptor-binding domain (RBD) and ACE2. This compound demonstrates potent neutralization against the BA.2 lineage and subsequent Omicron variants, and has shown capabilities in inhibiting SARS-CoV-2 replication in murine models. SARS-CoV-2-IN-120 is valuable for research applications focused on viral entry mechanisms and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-46 is an inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of approximately 25 μM. This compound demonstrates significant antiviral activity with low cytotoxicity, as indicated by an IC50 value of 7.4 μM against SARS-CoV-2. SARS-CoV-2 Mpro-IN-46 is suitable for research applications focused on understanding and combating coronavirus infections, particularly in the context of COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2 3CLpro-IN-21 is an irreversible and covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 0.03 µM. Additionally, it demonstrates activity against the SARS-CoV-1 3CLpro with an IC50 of 0.12 µM. This compound is valuable for investigative research into viral protease inhibition and potential therapeutic strategies against SARS-CoV-2 infections. -
SARS-CoV-2 Papain-like Protease Inhibitor
SARS-CoV-2-IN-106 is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), demonstrating IC50 values of 0.44 μM for enzymatic activity and 0.18 μM for viral replication. This compound is crucial for research into SARS-CoV-2 infection mechanisms and for the development of antiviral therapies targeting protease enzymes. Its efficacy makes it a valuable tool for studying coronavirus biology and potential treatments. -
SARS-CoV-2 PLpro/Mpro Inhibitor
SARS-CoV-2-IN-68 is a covalent inhibitor targeting the SARS-CoV-2 PLpro and Mpro proteases. This compound exhibits significant antiviral activity by binding to the Zn-finger domain of PLpro, thereby disrupting viral replication. It serves as a valuable tool in research focused on developing therapeutic strategies against SARS-CoV-2 infections. -
SARS-CoV-2 PLpro Inhibitor
9-Aminominocycline is a potent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), effectively disrupting its deubiquitination and protease activities with IC50 values of 4.55 µM and 4.15 µM, respectively. This compound demonstrates antiviral activity against SARS-CoV variants, including Delta and Omicron, with IC50 values of 1.04 µM and 2.35 µM in Calu-3 cells. It is a valuable research tool for investigating therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-92 is a potent inhibitor specifically targeting SARS-CoV-2 variants, with an EC50 value of 0.48 μM. This compound also exhibits inhibitory activity against SARS-CoV and MERS-CoV, demonstrating its broad-spectrum antiviral potential. SARS-CoV-2-IN-92 selectively blocks the interaction with the estrogen receptor alpha (ERα-Glu II), highlighting its relevance in research applications focused on viral inhibition and receptor modulation. -
SARS-CoV-2 RNA Degrader
MTDB-Alkyne is an alkyne-functionalized reagent designed for click chemistry applications. It serves as a synthetic precursor for Proximity-Induced Nucleic Acid Degraders (PINAD), facilitating the targeted degradation of SARS-CoV-2 RNA. Its unique mechanism allows for effective RNA manipulation, making it a valuable tool in antiviral research and therapies aimed at combating COVID-19. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-52 is a potent inhibitor of the SARS-CoV-2 main protease (MPro), demonstrating an EC50 of 0.0099 µM. It exhibits broad-spectrum antiviral activity against other coronaviruses, including MERS, OC43, and 229E, with EC50 values of 0.00961 µM, 0.138 µM, and 0.117 µM, respectively. This compound is suitable for research applications focusing on the development of antiviral therapeutics for COVID-19 and related viral infections. -
SARS-CoV-2 3CL Proteas Inhibitor
SARS-CoV-2 3CLpro-IN-13 is a highly effective inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 21 nM. This compound demonstrates significant anti-coronavirus activity, making it a valuable tool for research focused on SARS-CoV-2 inhibition and antiviral drug development. It is suitable for studies investigating the biochemical mechanisms underlying coronavirus replication and the potential therapeutic strategies against SARS-CoV-2. -
SARS-CoV PLpro Substrate
Z-Arg-Leu-Arg-Gly-Gly-AMC is a synthetic peptide substrate specifically designed for the SARS-CoV PLpro enzyme. This compound facilitates the study of PLpro's proteolytic activity and its role in viral replication. It serves as a valuable tool for researchers investigating the molecular mechanisms of SARS-CoV and developing potential antiviral strategies. -
SARS-CoV-2 PLpro and Mpro Inhibitor
LY1 is a selective covalent inhibitor targeting the SARS-CoV-2 proteases PLpro and Mpro, demonstrating Kd values of 1.5 μM and 2.3 μM for Mpro C145A and PLpro C111A, respectively. It exhibits potent antiviral activity with IC50 values of 0.12 μM against Mpro and 0.99 μM against PLpro. Additionally, LY1 showcases high selectivity, distinguishing itself from other kinases, human proteases, and metalloenzymes, making it a valuable tool for research into SARS-CoV-2 protease inhibition. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-86 is an inhibitor targeting the methyltransferases nsp14 and nsp16 of SARS-CoV-2. This compound, a derivative of Andrographolide, demonstrates significant antiviral activity with low toxicity, evidenced by a predicted LD50 of 700 mg/kg. It serves as a valuable research tool for studying SARS-CoV-2 replication and may contribute to therapeutic strategies against COVID-19. -
SARS-CoV-2 Main Protease Inhibitor
X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro), displaying an affinity with a Kd value of 0.057 μM. This compound effectively disrupts the proteolytic activity of Mpro, crucial for viral replication. X77 is primarily utilized in research applications aimed at understanding SARS-CoV-2 biology and developing antiviral therapeutics. -
SARS-CoV 3CLpro Inhibitor
GRL-0496 is a potent inhibitor of SARS-CoV 3CLpro, functioning through targeting the viral protease essential for replication. It demonstrates significant enzyme inhibition with an IC50 of 30 nM and exhibits antiviral activity with an EC50 of 6.9 μM against SARS-CoV. This compound is valuable for research into antiviral therapies and the development of inhibitors aimed at addressing coronavirus infections. -
SARS-CoV-2 3CLpro Inhibitor
CCF0058981 is a noncovalent inhibitor targeting the SARS-CoV-2 3CL protease (3CLpro), with an IC50 of 68 nM. This compound also demonstrates activity against the SARS-CoV-1 3CLpro, exhibiting an IC50 of 19 nM. CCF0058981 shows promising antiviral efficacy and is a valuable tool for research applications focused on COVID-19 and coronavirus protease inhibition. -
SARS-CoV-2 Mpro Inhibitor
TKB245 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating significant efficacy in preventing viral replication. This compound is effective in VeroE6 cells, making it a valuable tool for research on COVID-19 pathogenesis and therapeutics. Its role in protease inhibition provides insight into potential antiviral strategies against SARS-CoV-2. -
SARS-CoV-2 inhibitor
SARS-CoV-2-IN-39 is a SARS-CoV-2 inhibitor that functions by inhibiting the SKP2 protein and stabilizing BECN1. With an EC50 value of 1 μM, this compound demonstrates significant antiviral activity against SARS-CoV-2. It is suitable for research applications focusing on viral pathogenesis and the development of therapeutic strategies targeting coronavirus infections. -
SARS-CoV-2 Mpro Inhibitor
CDD-1845 is a potent non-covalent, non-peptide inhibitor of SARS-CoV-2 main protease (Mpro) with a Ki of 3 nM. This compound effectively inhibits various Mpro variants, including ΔP168, A173V, and ΔP168/A173V. CDD-1845 is intended for research applications focused on SARS-CoV-2 protease inhibition and therapeutic development against COVID-19. -
SARS-CoV-2 Inhibitor
Kobophenol A is an oligomeric stilbene that acts as a SARS-CoV-2 inhibitor by hindering the interaction between the ACE2 receptor and the S1-RBD, exhibiting an IC50 value of 1.81 μM. This compound effectively blocks viral infection in cellular models, with an EC50 of 71.6 μM. Additionally, Kobophenol A demonstrates inhibitory activity against partially purified rat brain protein kinase C (PKC), with an IC50 of 52 µM, making it a valuable tool for studies on viral pathogenesis and enzyme regulation. -
SARS-CoV-2 Inhibitor
PAV-104 is an identified inhibitor of SARS-CoV-2, targeting the nucleocapsid (N) protein. By disrupting the oligomerization of the nucleocapsid, PAV-104 effectively interferes with viral particle assembly, thereby impeding replication at a multiplicity of infection (MOI) of 0.01. This compound is a valuable tool for research into antiviral strategies and the mechanistic understanding of SARS-CoV-2 propagation. -
SARS-CoV-2 Inhibitor
MAT-POS-e194df51-1 is an orally active non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 37 nM. This compound exhibits significant cytotoxicity, demonstrated by EC50 values of 64 nM in A549-ACE2-TMPRSS2 cells and 126 nM in HeLa-ACE2 cells. MAT-POS-e194df51-1 can be utilized in research focusing on antiviral drug development and the pathway exploration of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Main Protease Inhibitor
(Rac)-X77 is a potent non-covalent inhibitor of the SARS-CoV-2 main protease (Mpro). It demonstrates strong binding affinity with a Kd value of 0.057 μM, making it valuable for research into antiviral strategies against SARS-CoV-2. This compound is useful for studying protease inhibition mechanisms and developing therapeutic interventions targeting viral replication. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-6 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 73 nM. This compound is critical for research focused on developing antiviral therapeutics against SARS-CoV-2 by targeting its main protease, which is essential for viral replication. Its efficacy makes it suitable for studies aimed at understanding the enzymatic mechanisms of the virus and the development of potential treatment strategies. -
SARS-CoV-2 3CL Protease Inhibitor
MK-7845 is a reversible covalent inhibitor targeting the 3CL protease of SARS-CoV-2, exhibiting an IC50 of 8.7 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the research of COVID-19 therapeutics. Its specificity for the 3CL protease supports investigations into the inhibition of viral replication and pathogenesis, facilitating the development of effective antiviral strategies.
